How effective is PARP inhibitor therapy for pancreatic cancer?

PARP inhibitors interfere with a DNA-repair pathway. Some pancreatic cancer cells already have difficulty repairing DNA because of an inherited or tumour-acquired change in another repair pathway. In that situation, blocking PARP may make it harder for the cancer cell to survive.

This approach is usually considered only when the cancer’s molecular information and previous treatment support it. Genetic counselling or testing may be discussed because an inherited change can affect relatives as well as treatment choices. A suitable test result does not ensure that the cancer will respond, and scans and symptoms remain important in judging benefit.

Ask whether both inherited and tumour testing are appropriate, and whether results are available before a treatment decision is needed. Share your full medicine list, including supplements. Your team may arrange regular blood tests and review kidney or liver function. Take doses exactly as prescribed and report side effects early rather than stopping treatment on your own.

Call your oncology team urgently for fever, new infection symptoms, unusual bleeding or bruising, severe breathlessness, chest pain, persistent vomiting or sudden profound weakness. These may need prompt evaluation during treatment, particularly if blood counts fall. Emergency symptoms such as collapse or severe breathing difficulty require immediate emergency care.

Ask what the genetic or tumour test shows, whether a PARP inhibitor is being used to maintain control or treat active disease, and what other options are available. Ask how response will be monitored, which blood results affect dosing, and what symptoms should trigger a same-day call.